Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600329 Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
65 GF Score
Price ¥36.43
GF Value ¥23.63
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Tianjin Pharmaceutical Da Ren Tang Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SHSE:600329 vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tianjin Pharmaceutical Da Ren Tang Group Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Margin of Safety % (DCF Earnings Based) falls into.


SHSE:600329
65GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of ¥36.43 is trading 54.2% above its estimated GF Value™ of ¥23.63. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for SHSE:600329:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ¥23.63 vs. price of ¥36.43 (54.2% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore2TZ:Germany
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
65GF Score

Get the complete analysis for SHSE:600329

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.43
Price
¥23.63
GF Value